Literature DB >> 11929815

Prevalence and spectrum of p53 mutations associated with smoking in breast cancer.

Kathleen Conway1, Sharon N Edmiston, Lisa Cui, S Scott Drouin, Jingzhong Pang, Mei He, Chiu-Kit Tse, Joseph Geradts, Lynn Dressler, Edison T Liu, Robert Millikan, Beth Newman.   

Abstract

To explore the role of smoking in breast cancer, we undertook a population-based study to evaluate the prevalence and spectrum of p53 mutations in the breast tumors of smokers and nonsmokers. We evaluated 456 archival invasive breast tumors for mutations in exons 4-8 of the p53 gene, using single-strand conformational polymorphism analysis and manual sequencing. Statistical analyses were performed to determine the association of p53 mutations with clinical and smoking characteristics. Of 108 mutations identified, 77 (71%) were point mutations and 31 (29%) were deletions or insertions. A higher prevalence of p53 mutations was found in the breast tumors of current smokers (36.5%; P = 0.02) compared with never smokers (23.6%), whereas fewer mutations were found in former smokers (16.2%; P = 0.09). After adjustment for age, race, menopausal status, clinical stage, tumor size, and family history of breast cancer, current smokers were significantly more likely to harbor any p53 mutation [odds ratio (OR), 2.11; 95% confidence interval (CI), 1.17-3.78], p53 transversions (OR, 3.37; 95% CI, 1.03-11.06), and G:C-->T:A transversions (OR, 10.53; 95% CI, 1.77-62.55) compared with never smokers. Stage at diagnosis did not account for the increase in p53 mutation-positive breast cancer among current smokers. Former smokers were also more likely than never smokers to harbor G:C-->T:A transversions (OR, 2.43; 95% CI, 0.37-15.73), although this association was not statistically significant. Among former smokers, the prevalence of p53 mutations varied with time since quitting: former smokers who quit smoking for longer than 1 year had a lower prevalence of p53 mutations (10.5% for 1-5 years and 12.9% for >5 years) than those who had stopped smoking within the year of their cancer diagnosis (26.3%). Our results indicate that cigarette smoking appears to modify the prevalence and spectrum of p53 mutations in breast tumors. Moreover, the difference in mutational spectra observed between smokers and nonsmokers is suggestive of the genotoxic effects of smoking in breast tissue.

Entities:  

Mesh:

Year:  2002        PMID: 11929815

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  45 in total

1.  Genetic polymorphisms of multiple DNA repair pathways impact age at diagnosis and TP53 mutations in breast cancer.

Authors:  Tasha R Smith; Wen Liu-Mares; Beth O Van Emburgh; Edward A Levine; Glenn O Allen; Jeff W Hill; Isildinha M Reis; Laura A Kresty; Mark D Pegram; Mark S Miller; Jennifer J Hu
Journal:  Carcinogenesis       Date:  2011-06-23       Impact factor: 4.944

Review 2.  Interplay between smoking-induced genotoxicity and altered signaling in pancreatic carcinogenesis.

Authors:  Navneet Momi; Sukhwinder Kaur; Moorthy P Ponnusamy; Sushil Kumar; Uwe A Wittel; Surinder K Batra
Journal:  Carcinogenesis       Date:  2012-05-23       Impact factor: 4.944

3.  The Association of Modifiable Breast Cancer Risk Factors and Somatic Genomic Alterations in Breast Tumors: The Cancer Genome Atlas Network.

Authors:  Yujing J Heng; Susan E Hankinson; Jun Wang; Ludmil B Alexandrov; Christine B Ambrosone; Victor P de Andrade; Adam M Brufsky; Fergus J Couch; Tari A King; Francesmary Modugno; Celine M Vachon; A Heather Eliassen; Rulla M Tamimi; Peter Kraft
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2020-01-13       Impact factor: 4.254

4.  Association of estrogen receptor-α A908G (K303R) mutation with breast cancer risk.

Authors:  Sakineh Abbasi; Mina Rasouli; Mehrnaz Nouri; Samira Kalbasi
Journal:  Int J Clin Exp Med       Date:  2012-11-18

5.  Breast cancer and exposure to tobacco smoke during potential windows of susceptibility.

Authors:  Alexandra J White; Aimee A D'Aloisio; Hazel B Nichols; Lisa A DeRoo; Dale P Sandler
Journal:  Cancer Causes Control       Date:  2017-05-18       Impact factor: 2.506

6.  Interaction between smoking and obesity and the risk of developing breast cancer among postmenopausal women: the Women's Health Initiative Observational Study.

Authors:  Juhua Luo; Kimberly Horn; Judith K Ockene; Michael S Simon; Marcia L Stefanick; Elisa Tong; Karen L Margolis
Journal:  Am J Epidemiol       Date:  2011-08-29       Impact factor: 4.897

7.  p53 regulates FAK expression in human tumor cells.

Authors:  Vita M Golubovskaya; Richard Finch; Frederick Kweh; Nicole A Massoll; Martha Campbell-Thompson; Margaret R Wallace; William G Cance
Journal:  Mol Carcinog       Date:  2008-05       Impact factor: 4.784

8.  Adiposity is associated with p53 gene mutations in breast cancer.

Authors:  Heather M Ochs-Balcom; Catalin Marian; Jing Nie; Theodore M Brasky; David S Goerlitz; Maurizio Trevisan; Stephen B Edge; Janet Winston; Deborah L Berry; Bhaskar V Kallakury; Jo L Freudenheim; Peter G Shields
Journal:  Breast Cancer Res Treat       Date:  2015-09-12       Impact factor: 4.872

9.  Associations between polycyclic aromatic hydrocarbon-related exposures and p53 mutations in breast tumors.

Authors:  Irina Mordukhovich; Pavel Rossner; Mary Beth Terry; Regina Santella; Yu-Jing Zhang; Hanina Hibshoosh; Lorenzo Memeo; Mahesh Mansukhani; Chang-Min Long; Gail Garbowski; Meenakshi Agrawal; Mia M Gaudet; Susan E Steck; Sharon K Sagiv; Sybil M Eng; Susan L Teitelbaum; Alfred I Neugut; Kathleen Conway-Dorsey; Marilie D Gammon
Journal:  Environ Health Perspect       Date:  2009-11-18       Impact factor: 9.031

10.  Mutations in p53, p53 protein overexpression and breast cancer survival.

Authors:  Pavel Rossner; Marilie D Gammon; Yu-Jing Zhang; Mary Beth Terry; Hanina Hibshoosh; Lorenzo Memeo; Mahesh Mansukhani; Chang-Min Long; Gail Garbowski; Meenakshi Agrawal; Tara S Kalra; Mia M Gaudet; Susan L Teitelbaum; Alfred I Neugut; Regina M Santella
Journal:  J Cell Mol Med       Date:  2008-10-16       Impact factor: 5.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.